Supports Moleculin’s Claim that Annamycin is a “Next Generation” Anthracycline HOUSTON, Feb. 20, 2020 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has received an independent assessment of the absence of […]